Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Abstract. Metabolic dysfunction-associated steatotic liver disease (MASLD), also called non-alcoholic fatty liver disease, is the most epidemic chronic liver disease worldwide. Metabolic dysfunction-associated steatohepatitis (MASH) is the critical stage of MASLD, and early diagnosis and treatment o...
Saved in:
| Main Authors: | Da Zhou, Jiangao Fan, Yuanyuan Ji |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2024-11-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000003355 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metabolic dysfunction-associated steatotic liver disease
by: Chieh Chen, et al.
Published: (2024-12-01) -
Microbiota and metabolic dysfunction associated with steatotic liver disease
by: Q. Zhu, et al.
Published: (2024-09-01) -
Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01) -
Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Emidio Scarpellini, et al.
Published: (2024-11-01) -
An overview of pathogenesis of metabolic dysfunction-associated steatotic liver disease
by: Shahid Habib, et al.
Published: (2024-11-01)